Denintuzumab mafodotin: Phase II started

Seattle Genetics began an open-label, U.S. Phase II trial to compare 3 mg/m 2 IV denintuzumab mafodotin every 3 weeks for up to 3 cycles with IV rituximab, IV ifosfamide, IV carboplatin and IV etoposi...